David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemother­a­py and ra­dio­ther­a­py are the cur­rent glad­i­a­tors of can­cer treat­ment, but they come with well-known lim­i­ta­tions and side-ef­fects. The emer­gence of im­munother­a­py — a fe­ro­cious new ti­tan in on­col­o­gist’s tool­box — takes the brakes off the im­mune sys­tem to kill can­cer cells with re­mark­able suc­cess in some cas­es, but the ap­proach is not al­ways ef­fec­tive. What makes cer­tain forms of can­cer so re­silient? Sci­en­tists may have fi­nal­ly pieced to­geth­er a tan­ta­liz­ing piece of the puz­zle, and a new biotech is bank­ing on a new ap­proach to fill the gap.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.